Phase 2
N=594
Improving Treatment Adherence in HIV-Infected Individuals
HIV Antiretroviral Therapy (ART) Adherence · Health Behavior
Bottom Line
View on ClinicalTrials.gov: NCT00247611 ↗Enrolled (actual)
594
Serious AEs
0.0%
Results posted
Dec 2013
Primary outcome: Primary: AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken — 72.89; 75.46; 74.86; 77.33 percent with 100% adherence — p=0.12
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- LifeWindows Intervention Sessions (Behavioral); Control (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Connecticut
- Primary completion
- Mar 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken |
72.89; 75.46; 74.86; 77.33; 80.36; 82.48 | 0.12 |
| PRIMARY Visual Analog Scale Measure of Adherence to ART |
42.61; 46.15; 45.71; 45.33; 43.27; 47.81 | 0.12 |
| SECONDARY Viral Load Count |
73.9; 70.3; 70.3; 77.0; 73.4; 75.0 | >0.50 |
Summary
This study will develop and evaluate the efficacy of an individualized, interactive, computer software program delivered in conjunction with clinical care in increasing and supporting antiretroviral therapy adherence in HIV-infected individuals.
Eligibility Criteria
Inclusion Criteria
- HIV-infected
- English-speaking
- Currently receiving treatment at one of the participating sites
- Currently receiving antiretroviral therapy
Exclusion Criteria
- Marked cognitive impairment
Data sourced from ClinicalTrials.gov (NCT00247611). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.